BioSpace News Archive

The global market for influenza diagnostics is slated to expand at a promising pace in the next few years as the incidences of influence are rising at a massive pace on the globe front.

Of late, there has been an increasing awareness regarding the therapeutic potential of stem cells for management of diseases which is boosting the growth of the stem cell therapy market.

Patents Related to P-selectin Expand Patent Life for Quercis’ Investigational Drug to Prevent and Treat Venous Thromboembolism in Cancer Patients and for Prevention and Treatment of COVID-19

While these numbers are sobering, more staggering are the number of people who have died. 18,266 people in Canada have been killed by COVID-19 since the start of this pandemic.

Noveome Biotherapeutics , Inc., a clinical stage biopharmaceutical company focused on developing next-generation biologics for the restoration of cellular integrity of damaged tissues, has appointed Ronald K. Poropatich, M.D., M.S., to the company’s Board of Directors.

BridgeBio Pharma, Inc. (Nasdaq: BBIO) (the “Company,” “we” or “BridgeBio”) announced today that it intends to offer, subject to market conditions and other factors, $400 million aggregate principal amount of convertible senior notes due 2029 (the “notes”) in a private offering (the “offering”) to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933

TScan Therapeutics, today announced the closing of an oversubscribed $100 million Series C financing.

Faze Medicines , a biotechnology company pioneering therapeutics based on the groundbreaking new science of biomolecular condensates, today announced that it has appointed Philip Vickers, Ph.D., as its chief executive officer (CEO).

Antios Therapeutics, Inc. (“Antios”) today announced that it has completed the Phase 1b clinical trial of ATI-2173, an Active Site Polymerase Inhibitor Nucleotide (ASPIN

Biohaven Pharmaceutical Holding Company Ltd.today announced preliminary net product revenue of NURTEC ODT (rimegepant) for the fourth quarter of 2020.